Navigation Links
Newly Appointed CEO, Wendy Nelson, PhD, Leads Boston Biotech Conferences in a New Direction
Date:10/11/2018

Boston Biotech Conferences, creator of exclusive peer-to-peer CEO meetings for the biotech community, announces the appointment of Wendy Nelson, PhD, as its new CEO.

Dr. Nelson has over 20 years of business development, project management, operational and R&D experience in the biotech industry. Most recently, Dr. Nelson was VP of Business Development, Marketing and Strategic Alliances at Frontage Laboratories. Prior to her decade in business development roles of increasing responsibility, Nelson had roles in project management and operations at Alantos Pharmaceuticals (acquired by Amgen) and R&D at Alkermes. Dr. Nelson is also President & Founder of the Boston Biotech Forum. She has significantly contributed to the life sciences community by building that series into one of the premier content-rich networking events in Boston biotech over the past eight years. In her new role, Dr. Nelson will re-energize the business with substantial developments including rebranding, added leadership, and updated offerings.

“It’s an exciting time for this company and I’m thrilled to assume the leadership role. I hope to leverage my experience and passion of running my own Boston Biotech Forum events to re-establishing this business in Boston and across the country. My goal is to continue to build the premier networking and highest quality conferences in the life sciences ecosystem,” said Dr. Nelson.

Boston Biotech Conferences recently announced Bob Buderi as the new Chairman. Along with the appointed Ambassador committee under Buderi’s chairmanship, Nelson and Buderi will work closely together to help the business better position its offering to shape the future of biotech.

“Wendy is a terrific addition to the team. She brings fantastic insight from an extensive network of experts in life sciences. Her experience in both biotech and biopharma is going to make a monumental impact on this business and its exciting future,” said Buderi.

To learn more about the new leadership, click here. Stay tuned for upcoming announcements regarding the company’s additional developments.

About Boston Biotech Conferences:
Boston Biotech Conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the biopharma community. These meetings convene the most relevant players in biotech to network, collaborate and leverage the experiences of their peers in an off-the-record setting. For more information, please visit: http://www.bostonbiotechconferences.com.

Contact:
Boston Biotech Conferences
Suzanne Carroll
suzanne@bbbiotechconference.com
+1 857-504-6707

Read the full story at https://www.prweb.com/releases/newly_appointed_ceo_wendy_nelson_phd_leads_boston_biotech_conferences_in_a_new_direction/prweb15822536.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. MedForward Launches Newly Redesigned MedForward.com, Now Offering Mobile Site Design Services to Increase Website Accessibility for Smartphones and Tablets
2. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
3. FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice
4. Vivid Learning Systems Announces Newly Designed Industry Websites for MSHA, Electrical Utility Safety, Healthcare and OSHA Compliance
5. Newly discovered mechanism propels micromotors
6. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
7. Biomedical Research Foundation (BRF) Recruits Two Eminent Scientists --Pradeep Garg, Ph.D., And Sudha Garg, Ph.D. -- To Run Newly-Created Louisiana Center For Molecular Imaging And Therapy
8. Hemostemix Meets with Newly Formed Clinical Trial Steering Committee
9. Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells
10. METTLER TOLEDO’s Newly Launched HE53 Halogen Moisture Analyzer Makes Moisture Analysis Accessible to Everyone
11. CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... ... 2018 , ... Shell’s Puget Sound Refinery recently presented the ... high-tech machine that turns plastic into prosthesis. The Million Waves Project collects and ... the usable plastic and turns it into 3D printed prosthetic limbs for children ...
(Date:10/2/2018)... ... October 02, 2018 , ... Finalists for the ... Bio-Energy) AssurEOR product line was chosen for its advancements in the production chemicals ... leading innovations in upstream oil applications that are positively impacting the industry. The ...
(Date:9/28/2018)... ... 2018 , ... GlycoMark®, Inc. has announced a partnership with ... the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions ... GlycoMark test to its network of physicians through its sales organization and MD ...
(Date:9/27/2018)... ... September 26, 2018 , ... Medable was named DPharm ... build the first human digitome, a digital representation of human health and disease, ... integration of all data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, ...
Breaking Biology Technology:
(Date:10/5/2018)... ... October 04, 2018 , ... CallTower Inc., ... present at Microsoft Ignite 2018, in Orlando, Florida, when Microsoft made a major ... statement about the new direction of Skype for Business Online, outlining the following ...
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... High dose ... some of the tests such as cardiac troponin has serious clinical complications. There is ... the exact prevalence is still unknown. , High dose of biotin supplement use ...
(Date:10/3/2018)... ... October 03, 2018 , ... ... development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a ... type 2 diabetes and progressive diabetic kidney disease in a four-site, pan-European ...
Breaking Biology News(10 mins):